NPC(SH:600713) Shang Hai Zheng Quan Bao·2025-12-10 17:42Group 1 - The company announced a stock incentive plan for 2025, involving the grant of 18 million restricted stocks, accounting for 1.37% of the total share capital [1][2] - The initial grant was adjusted from 16.3 million shares to 16.059 million shares due to five participants voluntarily giving up their rights [2] - The plan includes a reserved grant of 1.941 million shares to 29 core management members at a price of 2.54 yuan per share [4][6] Group 2 - The company’s subsidiary, Anhui Tianxing Pharmaceutical Group, plans to invest in a modern pharmaceutical logistics expansion project with a total investment not exceeding 397.53 million yuan [14][15] - The project will include the renovation of existing facilities and the construction of new storage buildings, covering an area of 58,518.7 m², with a construction period of approximately 2.92 years [15][20] - The project aims to enhance logistics capabilities and ensure supply chain stability, addressing the growing demand for pharmaceutical storage [15][16] Group 3 - The company reported a steady growth in revenue from 39.8 billion yuan in 2020 to nearly 53.7 billion yuan in 2024, with a compound annual growth rate (CAGR) of 7.64% [30] - The net profit increased from 678 million yuan in 2020 to over 1 billion yuan in 2024, with a CAGR of 15.23% [30] - The company aims to enhance its core competitiveness through innovation and strategic partnerships, focusing on the healthcare industry [31][32] Group 4 - The company has initiated a digital transformation project to enhance operational efficiency and customer service, with over 40 projects underway [33][34] - The company has received various awards for its logistics and technology advancements, including a "double five-star" rating for its central logistics center [33] - The company is committed to sustainable development and has established an ESG framework to guide its operations [39]